This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boguszewski, C. L. Articles by Carlsson, L. M. S. Search for Related Content PubMed PubMed Citation Articles by Boguszewski, C. L. Articles by Carlsson, L. M. S.

Increased Proportion of Circulating Non-22-Kilodalton Growth Hormone Isoforms in Short Children: A Possible Mechanism for Growth Failure¹

Research Center for Endocrinology and Metabolism, Department of Internal Medicine (C.L.B., B.C., L.M.S.C.), and International Pediatric Growth Research Center, Department of Pediatrics (C.J., M.C.S.B., S.R., K.A.W.), University of Göteborg, Göteborg, Sweden

Address all correspondence and requests for reprints to: Dr. Cesar L. Boguszewski, Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Bruna Stråket 16, S-413 45 Göteborg, Sweden. E-mail: cesar.boguszewski{at}ss.gu.se

Current knowledge about the interaction between GH and its receptor suggests that the molecular heterogeneity of circulating GH may have important implications for growth. The aim of this study was to investigate the proportion of circulating non-22-kDa GH isoforms in prepubertal children with short stature (height less than -2 SD score) of different etiologies. We have also evaluated the relationships among the ratio of non-22-kDa GH isoforms, auxology, and spontaneous GH secretion. The study groups consisted of 17 girls with Turner’s syndrome (TS), aged 3–13 yr; 25 children born small for gestational age (SGA) without postnatal catch-up growth, aged 3–13 yr; and 24 children with idiopathic short stature (ISS), aged 4–15 yr. The results were compared with those from 23 prepubertal healthy children of normal stature (height ± 2 SD score), aged 4–13 yr. Serum non-22-kDa GH levels, expressed as a percentage of the total GH concentration, were determined by the 22-kDa GH exclusion assay, which is based on immunomagnetic extraction of monomeric and dimeric 22-kDa GH from serum and quantitation of non-22-kDa GH using a polyclonal antibody-based GH assay. All samples were selected from spontaneous GH peaks in 24-h GH profiles. The median proportion of non-22-kDa GH isoforms was increased in children born SGA (9.8%; P = 0.05) and girls with TS (9.9%; P = 0.01), but not in the group of children with ISS (8.9%), compared with that in normal children (8.1%). Individually, increased proportions of non-22-kDa GH isoforms, with values more than 2 SD above the mean for the normal group, were observed in 5 girls with TS, 5 children born SGA, and 4 children with ISS. In children born SGA, the proportion of non-22-kDa GH isoforms was directly correlated with different estimates of spontaneous GH secretion [mean 24-h GH concentration (r = 0.41; P = 0.04), area under the curve over baseline (r = 0.41; P = 0.04), and GH peak area (r = 0.61; P = 0.003)], whereas it was inversely correlated with height SD score (r = -0.42; P = 0.04). In conclusion, an increased proportion of circulating non-22-kDa GH isoforms was observed at spontaneous GH peaks in some non-GH-deficient short children. Our results suggest that the ratio of non-22-kDa GH isoforms in the circulation may have important implications for normal and abnormal growth.

This article has been cited by other articles:

				Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, M. Jansen, B. J. Otten, J. J. G. Hoorweg-Nijman, T. Vulsma, W. H. Stokvis-Brantsma, C. W. Rouwe, et al. Final Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment in Three Dosages and Low Dose Estrogens J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1119 - 1125. [Abstract] [Full Text] [PDF]

				M. Sjoberg, T. Salazar, C. Espinosa, A. Dagnino, A. Avila, M. Eggers, F. Cassorla, P. Carvallo, and M. V. Mericq Study of GH Sensitivity in Chilean Patients with Idiopathic Short Stature J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4375 - 4381. [Abstract] [Full Text] [PDF]

				T. Sas, P. Mulder, and A. Hokken-Koelega Body Composition, Blood Pressure, and Lipid Metabolism before and during Long-Term Growth Hormone (GH) Treatment in Children with Short Stature Born Small for Gestational Age Either with or without GH Deficiency J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3786 - 3792. [Abstract] [Full Text]

				C. Arámburo, M. Luna, M. Carranza, M. Reyes, H. Martínez-Coria, and C. G. Scanes Growth Hormone Size Variants: Changes in the Pituitary During Development of the Chicken Experimental Biology and Medicine, January 1, 2000; 223(1): 67 - 74. [Abstract] [Full Text]

				T. Sas, W. de Waal, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3064 - 3070. [Abstract] [Full Text]

				M. Ishikawa, S. Yokoya, K. Tachibana, Y. Hasegawa, T. Yasuda, E. Tokuhiro, Y. Hashimoto, and T. Tanaka Serum Levels of 20-Kilodalton Human Growth Hormone (GH) Are Parallel Those of 22-Kilodalton Human GH in Normal and Short Children J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 98 - 104. [Abstract] [Full Text]

				T. Tsushima, Y. Katoh, Y. Miyachi, K. Chihara, A. Teramoto, M. Irie, and Y. Hashimoto Serum Concentration of 20K Human Growth Hormone (20K hGH) Measured by a Specific Enzyme-Linked Immunosorbent Assay J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 317 - 322. [Abstract] [Full Text]